Industry investors at the LSX Investival Showcase EU told biotech founders to prioritize technical validation, platform maturity and alternative financing to survive the funding gap between seed and late‑stage rounds. Panelists from Blackstone, Limerston Capital and Apposite Capital emphasized commercial readiness, clinical validation and founder clarity as key criteria for new investments. The discussion highlighted royalty financing and non‑VC models as rising options.